Ophthalmic compositions
The embodiments disclosed herein relate to ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors, and more particularly to methods for treating an ocular disease and/or condition using the disclosed compositions. According to aspects illustrated herein, there is provided a pharmaceutical composition that includes a calcineurin inhibitor or an mTOR inhibitor; a first surfactant with an HLB index greater than about 10; and a second surfactant with an HLB index of greater than about 13, wherein an absolute difference between the HLB index of the first surfactant and the HLB index of the second surfactant is greater than about 3, and wherein the composition forms mixed micelles.
1. A pharmaceutical composition comprising:
a calcineurin inhibitor or an mTOR inhibitor;
a first surfactant with an HLB index greater than about 10; and
a second surfactant with an HLB index of greater than about 13,
wherein an absolute difference between the HLB index of the first surfactant and the HLB index of the second surfactant is greater than about 3,
wherein the composition is in the form of mixed micelles having the first and second surfactants; and wherein the composition contains less than 2% by weight ethanol.
2. The pharmaceutical composition of claim 1 wherein the calcineurin inhibitor or the mTOR inhibitor is selected from one or more of voclosporin, cyclosporine A, pimecrolimus, tacrolimus, sirolimus, temsirolimus, everolimus, analogs thereof, pharmaceutically acceptable salts thereof, or combinations thereof.
3. The pharmaceutical composition of claim 1 wherein the composition is in the form of optically clear mixed micelles.
4. The pharmaceutical composition of claim 1 wherein the first surfactant is selected from a polyethylene glycol (PEG)-5-100 nonyl phenyl ether, tyloxapol, a PEG-fatty acid monoester surfactant, a PEG-glycerol fatty acid ester, and a PEG-sorbiton fatty acid ester.
5. The pharmaceutical composition of claim 4 wherein the PEG-fatty acid monoester surfactant is selected from PEG-15 oleate, PEG-20 laurate, PEG-20 oleate, PEG-20 stearate, PEG-32 laurate, PEG-32 oleate, PEG-32 stearate, PEG-40 laurate, PEG-40 oleate, and PEG-40 stearate.
6. The pharmaceutical composition of claim 4 wherein the PEG-glycerol fatty acid ester is selected from PEG-15 glyceryl laurate, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, and PEG-20 glyceryl stearate.
7. The pharmaceutical composition of claim 4 wherein the PEG-sorbiton fatty acid ester is selected from PEG-4 sorbiton monolaurate, PEG-4 sorbiton monostearate, PEG-5 sorbiton monooleate, PEG-20 sorbiton monolaurate, PEG-20 sorbiton monopalmitate, PEG-20 sorbiton monostearate, and PEG-20 sorbiton monooleate.
8. The pharmaceutical composition of claim 1 wherein the second surfactant is a polyethylene glycol (PEG)-alkyl ether surfactant or PEG-alkyl aryl ether surfactant.
9. The pharmaceutical composition of claim 8 wherein the second surfactant is a PEG 5-100 octyl phenyl ether.
10. The pharmaceutical composition of claim 9 wherein the PEG 5-100 octyl phenyl compound is selected from octoxynol-9, octoxynol-10, octoxynol-11, octoxynol-12, octoxynol-13, octoxynol-16, octoxynol-20, octoxynol-25, octoxynol-30, octoxynol-33, octoxynol-40, and octoxynol-70.
11. The pharmaceutical composition of claim 1 wherein the composition is an aqueous solution.
12. The pharmaceutical composition of claim 1 wherein the calcineurin inhibitor or mTOR inhibitor is delivered to a back of an eye.
13. The pharmaceutical composition of claim 1 wherein the composition is essentially free of short-chain alcohols.
14. A pharmaceutical composition comprising:
a calcineurin inhibitor or an mTOR inhibitor;
a first surfactant with an HLB index greater than about 10; and
a second surfactant with an HLB index of greater than about 13,
wherein an absolute difference between the HLB index of the first surfactant and the HLB index of the second surfactant is greater than about 3,
wherein the composition is in the form of an aqueous solution of mixed micelles having the first and second surfactants; and
wherein the composition contains less than 2% by weight ethanol.
15. The pharmaceutical composition of claim 14 wherein the calcineurin inhibitor or the mTOR inhibitor is selected from one or more of voclosporin, cyclosporine A, pimecrolimus, tacrolimus, sirolimus, temsirolimus, everolimus, analogs thereof, pharmaceutically acceptable salts thereof, or combinations thereof.
16. The pharmaceutical composition of claim 14 wherein the composition is optically clear.
17. The pharmaceutical composition of claim 14 wherein the first surfactant is selected from a polyethylene glycol (PEG)-5-100 nonyl phenyl ether, tyloxapol, a PEG-fatty acid monoester surfactant, a PEG-glycerol fatty acid ester, and a PEG-sorbiton fatty acid ester.
18. The pharmaceutical composition of claim 14 wherein the second surfactant is a polyethylene glycol (PEG)-alkyl ether surfactant or PEG-alkyl aryl ether surfactant.
19. The pharmaceutical composition of claim 14 wherein the calcineurin inhibitor or mTOR inhibitor is delivered to a back of an eye.
20. The pharmaceutical composition of claim 14 wherein the composition is free of short-chain alcohols.
21. A method for treating an ocular disease in a patient in need thereof, comprising administering topically to an eye of the patient a mixed micelle pharmaceutical composition comprising:
a calcineurin inhibitor or an mTOR inhibitor;
a first surfactant with an HLB index greater than about 10; and
a second surfactant with an HLB index of greater than about 13,
wherein an absolute difference between the HLB index of the first surfactant and the HLB index of the second surfactant is greater than about 3, wherein the composition is in the form of mixed micelles having the first and second surfactants, and wherein the composition contains less than 2% by weight ethanol.
22. The method of claim 21 wherein the calcineurin inhibitor or the mTOR inhibitor is selected from one or more of voclosporin, cyclosporine A, pimecrolimus, tacrolimus, sirolimus, temsirolimus, everolimus, analogs thereof, pharmaceutically acceptable salts thereof, or combinations thereof.
23. The method of claim 21 wherein the first surfactant is selected from a polyethylene glycol (PEG)-5-100 nonyl phenyl ether, tyloxapol, a PEG-fatty acid monoester surfactant, a PEG-glycerol fatty acid ester, and a PEG-sorbiton fatty acid ester.
24. The method of claim 23 wherein the PEG-fatty acid monoester surfactant is selected from PEG-15 oleate, PEG-20 laurate, PEG-20 oleate, PEG-20 stearate, PEG-32 laurate, PEG-32 oleate, PEG-32 stearate, PEG-40 laurate, PEG-40 oleate, and PEG-40 stearate; the PEG-glycerol fatty acid ester is selected from PEG-15 glyceryl laurate, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, and PEG-20 glyceryl stearate; and the PEG-sorbiton fatty acid ester is selected from PEG-4 sorbiton monolaurate, PEG-4 sorbiton monostearate, PEG-5 sorbiton monooleate, PEG-20 sorbiton monolaurate, PEG-20 sorbiton monopalmitate, PEG-20 sorbiton monostearate, and PEG-20 sorbiton monooleate.
25. The method of claim 21 wherein the second surfactant is a polyethylene glycol (PEG)-alkyl ether surfactant or PEG-alkyl aryl ether surfactant.
26. The method of claim 25 wherein the second surfactant is a PEG 5-100 octyl phenyl ether selected from octoxynol-9, octoxynol-10, octoxynol-11, octoxynol-12, octoxynol-13, octoxynol-16, octoxynol-20, octoxynol-25, octoxynol-30, octoxynol-33, octoxynol-40, and octoxynol-70.
27. The method of claim 21 further comprising delivering the calcineurin inhibitor or mTOR inhibitor to a back of an eye via the mixed micelle pharmaceutical composition.
28. The method of claim 21 wherein the ocular disease is an inflammatory ocular surface disease selected from the group consisting of dry eye syndrome (DES), Sjogren's syndrome, uveitis, conjunctivitis (pink eye), keratitis, keratoconjunctivitis, vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), autoimmune disorders of the ocular surface, cicatrizing conjunctivitis, blepharitis, scleritis, or an immune rejection of a corneal allograft.
29. The method of claim 21 wherein the composition is essentially free of short-chain alcohols.